When rheumatic heart disease causes both mitral regurgitation and mitral stenosis simultaneously, the resulting mixed mitral valve disease presents a narrow therapeutic window. The coexistence of both lesions restricts which pharmacological approaches can be safely applied.
This protocol is specific to rheumatic heart disease presenting as mixed mitral valve disease — the simultaneous presence of mitral regurgitation and mitral stenosis. This combination significantly limits the medical treatment options compared to either lesion managed in isolation.
Conversely, in mixed mitral valve disease, diuretic agents may be the only medical therapy available.
DOI: 10.1161/CIR.0000000000000921
View source ↗